Comparative assessment of prophylactic transfusions of platelet concentrates obtained by the PRP or buffy-coat methods, in patients undergoing allogeneic hematopoietic stem cell transplantation

被引:0
|
作者
Fernandez-Munoz, Hermogenes [1 ,2 ]
Plaza, Eva M. [1 ]
Miguel Rivera-Caravaca, Jose [1 ]
Jose Candela, Maria [1 ]
Romera, Marta [1 ,3 ]
De Arriba, Felipe [1 ]
Lozano, Maria L. [1 ]
Vicente, Vicente [1 ]
Heras, Inmaculada [1 ]
Castilla-Llorente, Cristina [1 ,4 ]
Rivera, Jose [1 ]
机构
[1] Univ Murcia, Hosp Univ Morales Meseguer, Ctr Reg Hemodonac, Serv Hematol & Oncol Med,CIBERER,IMIB Arrixaca, Murcia, Spain
[2] Hosp Univ Rafael Mendez, Serv Hematol & Hemoterapia, Lorca, Spain
[3] Hosp Univ Santa Lucia, Serv Hematol & Hemoterapia, Cartagena, Spain
[4] Inst Gustave Roussy, Serv Hematol, Villejuif, France
关键词
Buffy-coat; platelet-rich plasma; correct count increment; platelet transfusion; allogeneic hematopoietic cell transplant; whole blood derived platelets; platelet concentrates; bleeding outcomes; WHOLE-BLOOD; APHERESIS; INCREMENTS; REFRACTORINESS; ENGRAFTMENT; LEUKEMIA; EFFICACY; STORAGE; PLASMA; IMPACT;
D O I
10.1080/10245332.2018.1455434
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Whole blood-derived platelet concentrates can be obtained by the platelet-rich plasma (PRP-PCs) or the buffy-coat (BC-PCs) method. Few studies have shown that BC-PCs display lower in vitro platelet activation, but scarce information exists regarding transfusion efficacy. We have performed a retrospective study assessing platelet transfusion in patients undergoing allogeneic hematopoietic cell transplantation (AHCT) in our clinic, before and after the implementation of BC-PCs. Methods: We reviewed clinical records corresponding to 70 PRP-PCs and 86 BC-PCs prophylactic transfusions, which were performed to 55 AHCT patients. Transfusion efficacy was assessed by the 24-h post-transfusion corrected count increment (24-h CCI) and bleeding events. Clinical factors affecting transfusion outcome were also investigated. Results: Clinical characteristics and the total number of platelet transfusions were similar among groups. Mean donor exposure was 5.8 and 5.0 in each single PRP-PCs and BC-PCs transfusion, respectively (p < 0.01). The 24-h CCI was significantly higher in patients transfused with BC-PCs than in those receiving PRP-PCs (8.3[2.7-13.4] vs. 4.7[1.3-8.1]; p < 0.01). Independent predictors of poor platelet transfusion response included diagnosis other than acute leukemia (HR 8.30; 95% CI 1.96-35.22; p = 0.004), splenomegaly (HR 8.75; 95% CI 2.77-27.60; p < 0.001), graft versus host disease prophylaxis different from cyclosporine A and methotrexate (HR 3.96; 95% CI 1.55-10.14; p = 0.004) and PRP-PCs transfusion (HR 4.54; 95% CI 1.72-12.01; p = 0.002). There were no differences between both groups regarding the bleeding events. Conclusion: In the AHCT setting, we hypothesize that BC-PCs transfusion, when compared to PRP-PCs, results in higher CCI and reduced donor exposure, but provides no significant benefit regarding bleeding outcome.
引用
收藏
页码:712 / 718
页数:7
相关论文
共 48 条
  • [31] Sequential systematic anti-mold prophylaxis with micafungin and voriconazole results in very low incidence of invasive mold infections in patients undergoing allogeneic hematopoietic stem cell transplantation
    Rosillo, Claudia
    Avila, Ana Maria
    Huang, Yao-Ting
    Devlin, Sean
    Cho, Christina
    Montoro, Juan
    Maloy, Molly A.
    Papanicolaou, Genovefa A.
    Barba, Pere
    Perales, Miguel-Angel
    TRANSPLANT INFECTIOUS DISEASE, 2018, 20 (04)
  • [32] High EGFL7 expression may predict poor prognosis in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation
    Cheng, Zhiheng
    Dai, Yifeng
    Pang, Yifan
    Jiao, Yang
    Liu, Yan
    Cui, Longzhen
    Qian, Tingting
    Quan, Liang
    Cui, Wei
    Pan, Yue
    Ye, Xu
    Shi, Jinlong
    Fu, Lin
    CANCER BIOLOGY & THERAPY, 2019, 20 (10) : 1314 - 1318
  • [33] Significance of WT1 and multiparameter flow cytometry assessment in patients with chronic myelomonocytic leukemia receiving allogeneic hematopoietic stem cell transplantation
    Pan, Xinan
    Gao, Mengge
    Sun, Yuqian
    Zhou, Yang
    Wang, Ke
    Wang, Yu
    Xu, Lanping
    Zhang, Xiaohui
    Huang, Xiaojun
    Zhao, Xiao-Su
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2022, 44 (03) : 510 - 517
  • [34] Correlation Between the Kinetics of CD3+ Chimerism and the Incidence of Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
    Rupa-Matysek, J.
    Lewandowski, K.
    Nowak, W.
    Sawinski, K.
    Gil, L.
    Komarnicki, M.
    TRANSPLANTATION PROCEEDINGS, 2011, 43 (05) : 1915 - 1923
  • [35] High Alloreactivity of Low-Dose Prophylactic Donor Lymphocyte Infusion in Patients with Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation with an Alemtuzumab-Containing Conditioning Regimen
    Liga, Maria
    Triantafyllou, Evangelia
    Tiniakou, Maria
    Lambropoulou, Polyxeni
    Karakantza, Marina
    Zoumbos, Nicholas C.
    Spyridonidis, Alexandros
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (01) : 75 - 81
  • [36] Effect of cyclosporine a and polymorphisms in CYP2C19 and ABCC2 on the concentration of voriconazole in patients undergoing allogeneic hematopoietic stem cell transplantation
    Zeng, Guangting
    Shi, Lihong
    Li, Huilan
    Wang, Linlin
    Zhu, Miaomiao
    Luo, Jia
    Zhang, Zanling
    XENOBIOTICA, 2020, 50 (05) : 614 - 619
  • [37] Assessment of the Salivary Concentrations of Selected Immunological Components in Adult Patients in the Late Period after Allogeneic Hematopoietic Stem Cell Transplantation-A Translational Study
    Brodzikowska, Aniela
    Kochanska, Barbara
    Boguslawska-Kapala, Agnieszka
    Struzycka, Izabela
    Gorski, Bartlomiej
    Miskiewicz, Andrzej
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (03)
  • [38] Palonosetron versus first-generation 5-hydroxytryptamine type 3 receptor antagonists for emesis prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation
    Chou, Cheng-Wei
    Chen, Yeh-Ku
    Yu, Yuan-Bin
    Chang, Kuang-Hsi
    Hwang, Wen-Li
    Teng, Chieh-Lin Jerry
    ANNALS OF HEMATOLOGY, 2014, 93 (07) : 1225 - 1232
  • [39] Comparison of atrial fibrillation prevalence and in-hospital cardiovascular outcomes between patients undergoing allogeneic versus autologous hematopoietic stem cell transplantation: insights from the national inpatient sample
    Krishan, Satyam
    Asad, Zain Ul Abideen
    Quiroga, Dionisia
    Ghazi, Sanam M.
    Quartermaine, Cooper
    Braunstein, Zachary
    Kola-Kehinde, Onaopepo
    Shaaban, Adnan
    Habib, Alma
    Khan, Sarah
    Cheng, Richard
    Brammer, Jonathan E.
    Addison, Daniel
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [40] Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT)
    Efebera, Yvonne A.
    Geyer, Susan
    Andritsos, Leslie
    Vasu, Sumithira
    Jaglowski, Samantha
    Bingman, Anissa
    Blum, William
    Klisovic, Rebecca
    Hofmeister, Craig C.
    Benson, Don M.
    Penza, Sam
    Elder, Patrick
    Cortright, Katie
    Kitzler, Rhonda
    Coombes, Kevin
    O'Donnell, Lynn
    Daneault, Beth
    Bradbury, Hillary
    Zhang, Jianying
    Chen, Xilin
    Garman, Sabrina
    Ranganathan, Parvathi
    Yu, Xueyan
    Hofstetter, Jessica
    Yu, Jianhua
    Garzon, Ramiro
    Scrape, Scott R.
    Lozanski, Gerard
    Devine, Steven M.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (01) : 71 - 79